Clinical Rheumatology

, Volume 30, Issue 3, pp 399–401

Tuberculosis and anti-TNF treatment: experience of a central London hospital

  • Satveer Mankia
  • James E. Peters
  • Swan Kang
  • Samantha Moore
  • Michael R. Ehrenstein
Brief Report

DOI: 10.1007/s10067-010-1605-1

Cite this article as:
Mankia, S., Peters, J.E., Kang, S. et al. Clin Rheumatol (2011) 30: 399. doi:10.1007/s10067-010-1605-1

Abstract

Reactivation of latent tuberculosis (TB) is an established risk of anti-tumour necrosis factor α (anti-TNF) therapy. We report five cases of active TB occurring in 703 patients treated with anti-TNF therapy over a 10-year period in a central London hospital and review our screening practices for identifying latent TB prior to anti-TNF treatment. Four patients were receiving adalimumab and one patient etanercept at the time of TB diagnosis. Four of the five patients were born in countries with a high TB prevalence. Two of the five patients were healthcare workers. All patients had normal chest radiographs prior to anti-TNF treatment. Our data emphasise that country of origin is important in the determining risk of latent TB and that a normal chest radiograph does not exclude latent TB.

Keywords

Anti-TNFScreeningTB

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Satveer Mankia
    • 1
  • James E. Peters
    • 1
  • Swan Kang
    • 1
  • Samantha Moore
    • 1
  • Michael R. Ehrenstein
    • 1
  1. 1.Rheumatology DepartmentUniversity College HospitalLondonUK